Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CET

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
09:05a EMAAR PROPERTIES : Middle East to hand over Square offices this month; launches Residences, 3rd residential project in Jeddah Gate
09:05a GLENCORE : Russia sells share in country’s largest oil company
09:05a YDreams Global announces its first Virtual Reality licensing project in the United States
09:03a CARETECH : Preliminary Results
09:03a NATIONAL GRID : Sale of majority interest in NG Gas Distribution
09:03a M P EVANS : Disposal of interest in Agro Muko
09:03a DOLPHIN CAPITAL INVESTORS : 08.12.16Completion of the Playa Grande Disposal
09:03a ORIX : Auto to Begin Offering the “Ever Drive” Monitoring Service Designed to Reduce the Risk of Accidents Among Elderly Drivers
09:03a MYANMAR INVESTMENTS INTERNATIONAL : Unaudited Results for the Period Ended 30 September 2016
09:03a PLEXUS : AGM Statement
Latest news
Advertisement
Hot News 
-1.00%Poland agrees to buy back its second largest bank from UniCredit for $2.6 billion
-0.14%Mexico Collects $2.65 Billion from 2016 Oil Hedges
1.45%NIKKEI : Japan Inc warns of global trade contraction under Trump presidency - Reuters poll
Most Read News
12/07 HYUNDAI MOTOR : S.Korea worries about growing economic risks, amid impeachment push for President Park
12/07 MEDTRONIC : China says fines Medtronic local unit 118.5 million yuan for price fixing
12/07 Retailer Wal-Mart de Mexico to invest $1.3 billion in Mexico
12/07DJRussia Sells Stake in Oil Giant Rosneft to Glencore, Qatar - Update
12/07 TOKYO ELECTRIC POWER : Japan to increase loan to Fukushima operator Tepco to $123 billion -source
Most recommended articles
12/02 Platts considers first addition to Brent basket since 2007
03:01aDJPolish Firms to Buy Controlling Stake in Pekao from UniCredit for $2.57 Billion
02:55a EFG INTERNATIONAL : says to cut up to 450 jobs in BSI integration
02:54a SPORTS DIRECT INTERNATIONAL : profit slumps 57 percent after 'tough' period
02:53a NOVAE : sees FY underwriting contributions lower than its expectations